Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-08-02
1997-01-14
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514220, 514211, 540555, 540560, 540548, 540546, A61K 3155, C07D49514, C07D49804, C07D49504
Patent
active
055939880
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP92/01325, filed Oct. 12, 1992 and published as WO93/07129 Apr. 15, 1993.
TECHNICAL FIELD
The present invention relates to a therapeutic agent for osteoporosis containing, as an active ingredient, a certain azepine compound having superior bone resorption-inhibitory activity, a novel diazepine compound, a method for treating osteoporosis and use of said compound.
BACKGROUND ART
The osteoporosis is a syndrome which develops a symptom wherein a bone mass per unit volume is unusually decreased without causing any change in the chemical composition (ratio between organic substance and mineral substance) of the ossein per se and physiologically characterized by a decrease in protein, calcium and phosphorus in the bone.
The decrease in bone mass as a symptom includes that caused by physiological aging. Accordingly, the definition of the disease will be a remarkable decrease in bone mass which is greater than that caused by the physiological aging and the manifestation of clinical symptoms such as dorsolumbar pain, pathologic fracture, vertebral deformation and the like.
The osteoporosis proceeds with aging and generally damages vertebra and causes dorsolumbar pain and shortening of the height. In a very advanced case, long bone is also damaged to sometimes cause fracture. The femoral fractures seen in old people are said to be mostly due to senile osteoporosis.
The causes of the osteoporosis are diverse and include abnormal internal secretion inclusive of menopause, nutritional disorder and so on. The vitamin D preparations, calcium preparations, calcitonin preparations, bisphosphonate preparations and so on conventionally used for treating osteoporosis suffer from limitation on administration targets and unconclusive effects. As regards female hormone preparations, its dependable effects are associated with severe side effects such as genital cancer caused by a long-term use of the preparation.
Hence, the development of a therapeutic agent for osteoporosis, having reliable effects and high safety is strongly demanded.
In recent years, thionaphthene-2-carboxylic acid derivative and 3-phenyl-4H-1-benzopyran-4-one derivative (isoflavone derivative) having a completely different chemical structure from the aforementioned preparations have been reported to have bone resorption-inhibitory activity and to be useful as therapeutic agents for treating osteoporosis (A. J. Johannesson et al, Endocrinology, 117, P. 1508, EP-A-135172, EP-A-136569, EP-A-146921, U.S. Pat. No. 4,644,012).
As the derivative having bone resorption-inhibitory activity, (cycloalkylamino)methylenebis(phosphonic acid) derivative (U.S. Pat. No. 4,970,335), heterocyclic bisphosphonic acid derivative (U.S. Pat. No. 4,990,503) and benzofuroquinoline derivative (EP-A-357172) have been reported.
As the compounds having a diazepine skeleton, known are benzodiazepine compounds, thienodiazepine compounds, benzotriazolodiazepine compounds, benzimidazolodiazepine compounds and thienotriazolodiazepine compounds, having antianxiety, sedative and muscle-relaxing actions. Specific examples are bromazepam, clotiazepam, diazepam, flunitrazepam, flurazepam, lorazepam, medazepam, nitrazepam, oxazepam, azinazolam, alprazolam, brotizolam, estazolam, etizolam, midazolam and triazolam.
In addition, certain diazepine compounds such as devazepide and L-365260 are known to have cholecystokinin (CCK) antagonistic action or gastrin antagonistic action (Japanese Patent Unexamined Publication Nos. 63666/1986, 238069/1988 and 223290/1991 and W089/05812).
As the compounds having a platelet activating factor (PAF)-antagonistic action and expected to be an antiasthma agent and a circulatory drug, known are thienotriazolodiazepine compounds such as 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno[3, 2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 3-(4-(2-chlorophenyl)-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]-triazolo[4,3-a] [1,4]diazepin-2-yl)propionic morpholide, 4-(3-(4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo-[4
REFERENCES:
patent: 3872089 (1975-03-01), Hromatka et al.
patent: 4333944 (1982-06-01), Weber et al.
patent: 4959361 (1990-09-01), Walser
patent: 5286858 (1994-02-01), Moriwaki et al.
Okano, K. et al. Chemical Abstract 113:212028 (1990).
Tahara, T. et al. Chemical Abstract 80:133443 (1974).
Moriwaki, M. et al. Chemical Abstract 110:173267 (1989).
Moriwaki, M. et al. Chemical Abstract 112:216937 (1990).
Naka, Y. et al. Chemical Abstract 111:214514 (1989).
Moriwaki, M. et al. Chemical Abstract 112:77237 (1990).
Casals -Stenzel, J. et al. Chemical Abstract 105:146244 (1986).
Braquet, P. et al. Chemical Abstract 114:122431 (1991).
Walser, A. Chemical Abstract 114:143456 (1991).
Tahara, T. et al. Chemical Abstract 109:211096 (1988).
Braquet, P. et al. Chemical Abstract 116:128977 (1992).
Weber, K. H. et al. Chemical Abstract 115:114558 (1991).
Nakanishi, M. et al. Chemical Abstract 78:84416 (1973).
Nakanishi et al., "Thienodiazepine Derivatives", Chemical Abstracts, vol. 82, No. 9, 1975, Abstract No. 57752u (and JP-A-7411392)**.
Chiba Kenji
Manabe Shunichi
Moriwaki Minoru
Nakagawa Takashi
Nakamura Takeshi
Japan Tobacco Inc.
Tsang Cecilia
Wong King Lit
Yoshitomi Pharmaceutical Industries Ltd.
LandOfFree
Therapeutic agent for osteoporosis and diazepine compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for osteoporosis and diazepine compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for osteoporosis and diazepine compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1388330